Concepedia

Author

Filippo Spriano

Institute of Oncology ResearchORCID

Also Known As

Daniela Tomaselli, F. Spriano, Filippo Spriano

297

Publications

1.1K

Citations

18

H-Index

34

Concepts

All Affiliations

Institute of Oncology ResearchUniversità della Svizzera italianaSIB Swiss Institute of BioinformaticsMario Negri Institute for Pharmacological ResearchUniversity of Turin
FS

About

Filippo Spriano is an author at Institute of Oncology Research specializing in medicine, oncology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

187

2

Cell Biology

5

5

130

3

Biochemistry

2

2

45

4

Health Sciences

1

1

28

5

Natural Sciences

1

1

25

Filippo Spriano

×

25

Publications

793

Citations

17

H-Index

YearCitations

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

Chiara Tarantelli, Eugenio Gaudio, Alberto J. Arribas,

Clinical Cancer Research

2017

117

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

Filippo Spriano, Eugenio Gaudio, Luciano Cascione,

Blood Advances

2020

70

The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents

Filippo Spriano, Elaine Y. Chung, Eugenio Gaudio,

Clinical Cancer Research

2019

67

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Stuart W. Hicks, Chiara Tarantelli, Alan Wilhem,

Haematologica

2019

43

Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer

Tiziano Bernasocchi, Geniver El Tekle, Marco Bolis,

Nature Communications

2021

42

Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma

Elena Bernasconi, Eugenio Gaudio, Pascale Lejeune,

British Journal of Haematology

2017

40

Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

Chiara Tarantelli, Martin Lange, Eugenio Gaudio,

Blood Advances

2020

39

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano,

Haematologica

2020

38

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

Valentina Restelli, Monica Lupi, Rosaria Chilà,

Molecular Cancer Therapeutics

2019

35

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

Alberto J. Arribas, Sara Napoli, Luciano Cascione,

Haematologica

2022

29

Page 1